Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-164P is a pseudogene member of the U6 small nuclear RNA gene family[2][6]. U6 snRNAs are non-coding RNAs that play an essential role in the splicing of pre-mRNA as part of the spliceosome[3]. However, the "pseudogene" designation for RNU6-164P means it is a non-functional, typically non-expressed genomic copy generated during evolution, often through retrotransposition and not subject to the selective pressures or functions of its parental U6 snRNA gene[4][5][6]. Pseudogenes like RNU6-164P are not transcribed to form active products and do not have roles as drug targets or molecular receptors, nor are they involved in characterized cellular or disease processes[4][6]. In summary, "RNA, U6 small nuclear 164, pseudogene" (RNU6-164P) is a non-functional sequence related to the U6 family of spliceosomal RNAs, with no direct therapeutic, diagnostic, or biological target significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 164, pseudogene (RNU6-164P).